Tuesday, October 22, 2024
, a groundbreaking diagnostics company founded on the research of at The , recently was selected to join the prestigious .
The recognition solidifies both CxPM and HSC鈥檚 place at the forefront of the global effort to drive innovation in Alzheimer鈥檚 care and diagnostics.
CxPM, a spinout from O鈥橞ryant鈥檚 laboratory at HSC, was founded to advance his pioneering work on blood-based biomarkers for Alzheimer鈥檚 disease and other neurodegenerative conditions. O鈥橞ryant, the founder of CxPM, is also a professor of family medicine at HSC and executive director of HSC鈥檚 Institute for Translational Research. His research forms the backbone of CxPM鈥檚 mission to improve early detection and treatment strategies for Alzheimer鈥檚.
鈥淚鈥檓 excited and humbled by the achievement of the CxPM team,鈥� O鈥橞ryant said. 鈥淚 embarked on this journey of creating a blood test for Alzheimer鈥檚 detection in primary care because of my own clinical and personal experiences. I鈥檓 thrilled to see this soon come to fruition in clinics.鈥�
Dr. Sid O鈥橞ryant, Professor, , and 鈥� Executive Director
HSC maintains a collaborative relationship with CxPM, through sponsored research activities, representation on the CxPM board, and prosecution of patent applications in a strong, global intellectual property portfolio. Because of this mutual respect and cooperative attitude by HSC and CxPM, O鈥橞ryant鈥檚 discoveries are now poised to make an even larger impact on Alzheimer鈥檚 care.
Joining the Alzheimer鈥檚 Moonshot community marks a significant milestone in CxPM鈥檚 journey. As the company seeks to expand its operations and raise additional capital, this exclusive program offers invaluable access to a network of investors, collaborators and strategic partners. StartUp Health Alzheimer鈥檚 Moonshot initiative is dedicated to advancing solutions to prevent, diagnose and cure Alzheimer鈥檚, a disease affecting more than 55 million people worldwide.
By joining the community, CxPM will gain access to mentorship, global collaborations and the opportunity to enhance its impact through partnerships with other innovators focused on Alzheimer鈥檚 care.
O鈥橞ryant鈥檚 vision and HSC鈥檚 ongoing involvement in CxPM have positioned the company as a leader in precision diagnostics for Alzheimer鈥檚 disease. This achievement highlights the role of academic research and innovation in addressing one of the world鈥檚 most challenging diseases.
鈥淲e are deeply honored to be a part of the Alzheimer鈥檚 Moonshot initiative,鈥� CxPM CEO Danguole Altman said. 鈥淭he collaboration between Cx Precision Medicine and HSC has been instrumental in bringing precision diagnostics to Alzheimer鈥檚 care. This will enable us to enhance our real-world impact on patients鈥� lives.鈥�
From - Research by Nicole Luna